DBVT vs. OCGN, EDIT, VYGR, ALLO, FATE, CCCC, JSPR, AURA, TRML, and AVXL
Should you be buying DBV Technologies stock or one of its competitors? The main competitors of DBV Technologies include Ocugen (OCGN), Editas Medicine (EDIT), Voyager Therapeutics (VYGR), Allogene Therapeutics (ALLO), Fate Therapeutics (FATE), C4 Therapeutics (CCCC), Jasper Therapeutics (JSPR), Aura Biosciences (AURA), Tourmaline Bio (TRML), and Anavex Life Sciences (AVXL). These companies are all part of the "biological products, except diagnostic" industry.
Ocugen (NASDAQ:OCGN) and DBV Technologies (NASDAQ:DBVT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, community ranking, institutional ownership, earnings, valuation and dividends.
In the previous week, Ocugen had 2 more articles in the media than DBV Technologies. MarketBeat recorded 9 mentions for Ocugen and 7 mentions for DBV Technologies. DBV Technologies' average media sentiment score of 0.18 beat Ocugen's score of 0.13 indicating that Ocugen is being referred to more favorably in the media.
Ocugen has a beta of 3.49, indicating that its share price is 249% more volatile than the S&P 500. Comparatively, DBV Technologies has a beta of 0.73, indicating that its share price is 27% less volatile than the S&P 500.
Ocugen has higher earnings, but lower revenue than DBV Technologies. Ocugen is trading at a lower price-to-earnings ratio than DBV Technologies, indicating that it is currently the more affordable of the two stocks.
10.3% of Ocugen shares are held by institutional investors. Comparatively, 71.7% of DBV Technologies shares are held by institutional investors. 3.5% of Ocugen shares are held by company insiders. Comparatively, 1.9% of DBV Technologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
DBV Technologies received 297 more outperform votes than Ocugen when rated by MarketBeat users. However, 68.92% of users gave Ocugen an outperform vote while only 56.92% of users gave DBV Technologies an outperform vote.
Ocugen presently has a consensus price target of $4.67, indicating a potential upside of 169.75%. DBV Technologies has a consensus price target of $3.33, indicating a potential upside of 495.24%. Given Ocugen's higher probable upside, analysts clearly believe DBV Technologies is more favorable than Ocugen.
Ocugen has a net margin of 0.00% compared to Ocugen's net margin of -530.89%. Ocugen's return on equity of -56.76% beat DBV Technologies' return on equity.
Summary
Ocugen beats DBV Technologies on 11 of the 18 factors compared between the two stocks.
Get DBV Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DBVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
DBV Technologies Competitors List
Related Companies and Tools
